Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Blastomycosis in immunocompromised patients

P G Pappas1, M G Threlkeld, G D Bedsole

  • 1Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine 35294-0006.

Medicine
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ProAD - A database of rotary ion-translocating ATPases in prokaryotic genomes.

Frontiers in molecular biosciences·2025
Same author

Towards practical applications in quantum computational biology.

Nature computational science·2024
Same author

Multicenter Registry of Patients Receiving Systemic Mold-Active Triazoles for the Management of Invasive Fungal Infections.

Infectious diseases and therapy·2022
Same author

Re: 'Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteremia' by Weis et al.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019
Same author

Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipients.

Transplant infectious disease : an official journal of the Transplantation Society·2018
Same author

Management of an Outbreak of Exophiala dermatitidis Bloodstream Infections at an Outpatient Oncology Clinic.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2017
Same journal

Mortality trends and projections for type 2 diabetes with concomitant Parkinson's versus Alzheimer's disease among older United States adults, 1999-2023: A retrospective cohort study.

Medicine·2026
Same journal

The causal relationship between the palmitoylation gene ZDHHC13 and ulcerative colitis: A Mendelian randomization study implicating CD62L-monocyte AC.

Medicine·2026
Same journal

Intraoperative outcomes of 2-dose indocyanine green fluorescence imaging strategies versus white light in laparoscopic cholecystectomy for cystic duct stones: A retrospective comparative study.

Medicine·2026
Same journal

Development and internal validation of a risk prediction model for gastric precancerous lesions integrating Helicobacter pylori serologic typing and host susceptibility polymorphisms.

Medicine·2026
Same journal

Causal effects of circulating inflammatory proteins on COPD: A Mendelian randomization study.

Medicine·2026
Same journal

Laparoscopic duodenojejunostomy for recurrent acute pancreatitis associated with superior mesenteric artery syndrome in a medically complex patient: A case report and literature review.

Medicine·2026
See all related articles

Blastomycosis is increasingly seen in immunocompromised patients, presenting as a more aggressive disease. Early, aggressive amphotericin B therapy is recommended for these individuals.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Immunology

Background:

  • Blastomycosis is an endemic mycosis historically less linked to immune dysfunction.
  • Emerging data suggest a higher prevalence of blastomycosis in immunocompromised individuals than previously acknowledged.

Purpose of the Study:

  • To investigate the changing incidence and clinical characteristics of blastomycosis in immunocompromised patients.
  • To evaluate the outcomes and therapeutic strategies for blastomycosis in this patient population.

Main Methods:

  • Retrospective analysis of patient data over a 15-year period (1978-1991).
  • Comparison of blastomycosis incidence and severity between immunocompromised and normal hosts.
  • Review of treatment responses and patient mortality.

Related Experiment Videos

Main Results:

  • A significant increase in blastomycosis cases among immunocompromised patients, from 3% (1956-1977) to 24% (1978-1991).
  • Blastomycosis exhibited more aggressive behavior in immunocompromised hosts, with nearly 30% mortality and frequent multi-organ/CNS involvement.
  • Persistent blastomycosis was noted in one-third of patients who died from other causes.

Conclusions:

  • Blastomycosis should be considered an opportunistic pathogen in immunocompromised individuals, especially in endemic areas.
  • Early and aggressive treatment with amphotericin B is crucial for immunocompromised patients with blastomycosis.
  • Azole therapy may be suitable for suppressive treatment post-amphotericin B, with caution advised for primary use in this group.